Company profile RVMD

Revolution Medicines Inc
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inheren...tly rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets. Show More
Quarter analysis & expected interest

There is not enough data for Revolution Medicines near me to provide analysis

Correlation between past revenue and Revolution Medicines near me search interest

There is not enough data for Revolution Medicines near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Revolution Medicines login to provide analysis

Correlation between past revenue and Revolution Medicines login search interest

There is not enough data for Revolution Medicines login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Revolution Medicines clinical trials to provide analysis

Correlation between past revenue and Revolution Medicines clinical trials search interest

There is not enough data for Revolution Medicines clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-4630 inhibitor to provide analysis

Correlation between past revenue and RMC-4630 inhibitor search interest

There is not enough data for RMC-4630 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-4630 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-5845 inhibitor to provide analysis

Correlation between past revenue and RMC-5845 inhibitor search interest

There is not enough data for RMC-5845 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-5845 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-5552 inhibitor to provide analysis

Correlation between past revenue and RMC-5552 inhibitor search interest

There is not enough data for RMC-5552 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-5552 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-6291 inhibitor to provide analysis

Correlation between past revenue and RMC-6291 inhibitor search interest

There is not enough data for RMC-6291 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-6291 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-6236 inhibitor to provide analysis

Correlation between past revenue and RMC-6236 inhibitor search interest

There is not enough data for RMC-6236 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-6236 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Revolution Medicines stock news to provide analysis

Correlation between past revenue and Revolution Medicines stock news search interest

There is not enough data for Revolution Medicines stock news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines stock news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for RVMD
Earnings date: 2024-02-26 After close
Company name: Revolution Medicines Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-21T13:05:00-07:00

GlobeNewswire
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

2026-10-21T15:10:21.599958992Z

Analyst Upgrades
TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target

2026-10-20T05:00:00-07:00

GlobeNewswire
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

2026-10-19T13:26:44.143736397Z

Analyst Upgrades
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

2026-10-16T17:06:17.54535797Z

Analyst Upgrades
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

2026-10-16T17:06:11Z

Analyst Upgrades
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

2026-10-16T15:02:49.41272297Z

Analyst Upgrades
William Blair Initiates Coverage On Revolution Medicines with Outperform Rating

2026-10-15T06:45:40-07:00

GlobeNewswire
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

2026-10-15T10:10:23.997055148Z

Analyst Upgrades
Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target

2026-10-14T13:41:12.076973215Z

Analyst Upgrades
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260

2026-10-08T14:54:15.438373029Z

Analyst Upgrades
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

2026-10-07T17:06:56.732913595Z

Analyst Upgrades
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

2026-09-28T16:55:49.576572301Z

Analyst Upgrades
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

2026-09-28T08:00:00-04:00

PR Newswire
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

2026-09-24T12:21:02.87015662Z

Analyst Upgrades
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target